TRENDING :  Market Movers  |  Top 50   AAPL (0%)    TSLA (0%)    TVIX (0%)    RIOT (0%)    QURE (0%)    QQQ (0%)    QCOM (0%)    PSTG (0%)    PEI (0%)    PAH (0%)    MCD (0%)    KO (0%)    JPM (0%)    IVC (0%)    IMDZ (0%)    GS (0%)    GOOGL (0%)    FDX (0%)    FCEL (0%)    FB (0%)    EA (0%)    CRM (0%)    CBS (0%)    BILI (0%)    BIDU (0%)

 AZN - Astrazeneca PLC

$40.43 [0][0%]

Next Earnings

5/17/2019

BMO

Recommend
Trade Idea »



ANALYST RATINGS

Quarterly Rating Chart
Rating

2


1=Strong Buy, 2=Buy, 3=Hold, 4=Underperform, 5=Sell
Price Targets
High $48.00
Low $42.00
Average $45.00
Current $40.43

CompanyAnalyst NamePT ActionActionRatingTargetDate
SunTrust Robinson HumphreyAnnouncesInitiates Coverage OnBuy$48.0012/14/18
JefferiesAnnouncesAssumesHold$42.0012/11/18
*Last 90 days

OPEN RECOMMENDATIONS

No recommendations found.


This list is limited to recommendations made in last 7 days only. Subscribe to a service to see all their recommendations.

TRADERS TRACKING $AZN

TRENDING ARTICLES



Pre-Market Most Active for Feb 20, 2019 : NRZ, CVS, NXTM, AZN, CHL, ARR, UL, TSLA, AMD, SQQQ, TVIX, UNIT

02/20/19
The NASDAQ 100 Pre Market Indicator is down 2 09 to 7 064 52 The total Pre Market volume is currently 4 121 282 shares traded The following are the most active stocks for the pre market session New Residential Investment Corp NRZ is 0 54 at 16 48 with 2 205

Merck's (MRK) Stock Up Almost 50% in a Year: Here's Why

02/19/19
In the past year Merck amp Co Inc MRK has been one of the biggest gainers along with Eli Lilly LLY 160 Merck s stock has risen 45 2 in the past year compared with a 7 4 increase for the industry Merck s performance in 2018 was supported by strong quarterly results

2 Pharma Stocks in the Middle of an Oncology Sales Explosion

02/19/19
Global spending on cancer drugs has soared in recent years along with the number of expensive new treatments reaching patients in need of new options Roche NASDAQOTH RHHBY led the industry with around 26 billion in oncology sales last year but losses from aging brands will

Pre-Market Most Active for Feb 19, 2019 : MT, AZN, WMT, ITUB, NVO, SBGL

02/19/19
The NASDAQ 100 Pre Market Indicator is down 14 08 to 7 041 1 The total Pre Market volume is currently 5 355 331 shares traded The following are the most active stocks for the pre market session ArcelorMittal MT is 0 68 at 22 40 with 1 109 133 shares traded

Strength Seen in AstraZeneca (AZN): Stock Soars 9.3%

02/15/19
AstraZeneca PLC AZN was a big mover last session as the company saw its shares rise more than 9 on the day The move came on solid volume too with far more shares changing hands than in a normal session This breaks the recent trend of the company as the stock is now trading above the

Why Marathon Oil, AstraZeneca, and Bloomin' Brands Jumped Today

02/14/19
Thursday was a volatile day on Wall Street as major stock indexes lost a lot of ground early in the day but then rebounded to finished mixed Gains for the Nasdaq Composite came even as Dow Jones Industrial Average 160 fell modestly and although investors spent much of

AstraZeneca Earnings: AZN Stock Zooms Higher on Q4 Beat

02/14/19
InvestorPlace Stock Market News Stock Advice amp Trading Tips AstraZeneca earnings for the fourth quarter of 2018 has AZN stock heading higher on Thursday Source Shutterstock AstraZeneca NYSE AZN reported earnings per share of 1 58 for the fourth quarter of the

Ironwood (IRWD) Q4 Earnings & Revenues Beat, Shares Rise

02/14/19
Ironwood Pharmaceuticals Inc IRWD incurred fourth quarter 2018 adjusted loss of 2 cents per share narrower than the Zacks Consensus Estimate of a loss of 17 cents as well as the loss of 14 cents in the year ago period Total revenues in the fourth quarter were 130 7 million reflecting

Bullish Two Hundred Day Moving Average Cross - AZN

02/14/19
In trading on Thursday shares of AstraZeneca plc Symbol AZN crossed above their 200 day moving average of 37 69 changing hands as high as 39 76 per share AstraZeneca plc shares are currently trading up about 8 4 on the day The chart below shows the one year performance of AZN

BMY vs. AZN: Which Stock Is the Better Value Option?

02/14/19
Investors with an interest in Large Cap Pharmaceuticals stocks have likely encountered both Bristol Myers Squibb BMY and Astrazeneca AZN But which of these two stocks is more attractive to value investors We ll need to take a closer look to find out There are plenty of strategies

AstraZeneca's (AZN) Q4 Earnings Beat, New Drugs Drive Sales

02/14/19
AstraZeneca plc AZN beat the Zacks Consensus Estimate for both earnings and sales in the fourth quarter of 2018 Pascal Soriot AstraZeneca s chief executive officer said AstraZeneca has returned to growth as its product sales grew for two consecutive quarters Per Soriot 2019 will be

Why Ironwood's Shares Climbed 11.7% on Wednesday

02/13/19
What happened After reporting fourth quarter financial results that were better than expected on both the top and bottom line and updating investors on its plans to split into two companies Ironwood Pharmaceuticals NASDAQ IRWD surged 11 7 higher today So

Pre-Market Earnings Report for February 14, 2019 : KO, DUK, CME, WM, ZTS, IQV, CCEP, PPL, TU, AZN, INCY, AEE

02/13/19
The following companies are expected to repor t earnings prior to market open on 02 14 2019 Visit our Earnings Calendar for a full list of expected earnings releases Coca Cola Company KO is reporting for the quarter ending December 31 2018 The

AstraZeneca: Fasenra Gets FDA's ODD For Hypereosinophilic Syndrome - Quick Facts

02/06/19
AstraZeneca: Fasenra Gets FDA's ODD For Hypereosinophilic Syndrome - Quick Facts

AstraZeneca: Fasenra Gets FDA's ODD For Hypereosinophilic Syndrome - Quick Facts

02/06/19
AstraZeneca: Fasenra Gets FDA's ODD For Hypereosinophilic Syndrome - Quick Facts

AstraZeneca: RSV Medicine MEDI8897 Gets FDA's BTD, EMA's PRIME Eligibility

02/05/19
AstraZeneca: RSV Medicine MEDI8897 Gets FDA's BTD, EMA's PRIME Eligibility

AstraZeneca: RSV Medicine MEDI8897 Gets FDA's BTD, EMA's PRIME Eligibility

02/05/19
AstraZeneca: RSV Medicine MEDI8897 Gets FDA's BTD, EMA's PRIME Eligibility

Why Astrazeneca (AZN) Could Beat Earnings Estimates Again

02/04/19
Looking for a stock that has been consistently beating earnings estimates and might be well positioned to keep the streak alive in its nex t quarterly report Astrazeneca AZN which belongs to the Zacks Large Cap Pharmaceuticals industry could be a great candidate to consider

Alkermes Sinks as FDA Refuses to Approve Depression Drug

02/04/19
Alkermes Plc ALKS announced that the FDA has issued a Complete Response Letter CRL related to its new drug application NDA for ALKS 5461 The NDA sought approval for the candidate as an adjunctive treatment of major depressive disorder MDD The regulatory authority refused

AstraZeneca Announces Completion Of Divestment Of US Rights To Synagis

01/25/19
AstraZeneca Announces Completion Of Divestment Of US Rights To Synagis

AstraZeneca Announces Completion Of Divestment Of US Rights To Synagis

01/25/19
AstraZeneca Announces Completion Of Divestment Of US Rights To Synagis